American Society of Hematology Annual Meeting

Prescribing Patterns Differ for Rural, Urban Patients with CLL or SLL

December 11th 2023, 10:00pm

Video

Where a patient lives may affect what kind of treatment they are offered for their CLL or SLL. However, second opinions and learning about one’s cancer diagnosis can help.

Jakafi Results in Improved Control of Steroid Refractor/Dependent cGVHD

December 11th 2023, 8:00pm

Article

The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared with the best available treatment.

MRD Status Can Help Guide Treatments in NPM1-Mutated AML

December 11th 2023, 2:00pm

Article

Molecular minimal residual disease status may offer clues as to which patients with acute monocytic leukemia will benefit from certain therapies.

Stem Cell Transplants Improves Survival Without Progression in Relapsed LBCL Subset

December 11th 2023, 2:00am

Article

Autologous hematopoietic cell transplantation, compared with CAR-T cell therapy, resulted in lower rates of relapse and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.

Navitoclax Plus Jakafi Improves Spleen Volume Reductions in Myelofibrosis

December 11th 2023, 12:00am

Article

The recent phase 3 TRANSFORM-1 study concluded that navitoclax combined with Jakafi showed significant spleen volume reductions in patients with myelofibrosis.

Orca-T Shows Promise in Intermediate-/High-Risk MDS

December 10th 2023, 10:00pm

Article

The stem cell thrapy, Orca-T led to promising relapse-free and overall survival rates in patients with intermediate- to high-risk myelodysplastic syndrome.

Yescarta Improves Survival for Patients With Large B-Cell Lymphoma

December 10th 2023, 8:00pm

Article

Data from the ZUMA-7 trial shows that age alone should not be a barrier of consideration of administering CAR-T cell therapy to patients with large B-cell lymphoma, says Dr. Marie José Kersten.

AI Model Tells the Difference Between MPN Subtypes

December 10th 2023, 6:00pm

Video

An artificial intelligence platform was able to tell the difference between patients with prefibrotic primary myelofibrosis and essential thrombocythemia. However, an expert says that there are considerations that patients must remember when it comes to the use of such programs.

Abecma May Improve Quality of Life in Previously Treated Myeloma

December 10th 2023, 4:00pm

Article

The quality-of-life improvement with Abecma in patients with relapsed/refractory multiple myeloma was greater when compared with standard regimens.

Tecartus Induces Responses in Real-World Population of High-Risk R/R MCL

December 10th 2023, 12:25am

Article

Tecartus is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.